This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Lipoprotein Research Stockholm Ab, The Kitasato Institute. Active years: 2026.
Company Filing History:
1 out of 1 
1 out of 102 Years Active: 2026
Title: Matteo Pedrelli: Innovator in PCSK9 Inhibition
Introduction
Matteo Pedrelli is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). His work is crucial in addressing various health issues related to cholesterol regulation.
Latest Patents
Matteo Pedrelli holds a patent for a low-molecular weight compound that acts as a PCSK9 inhibitor. This patent, titled "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor," describes a compound that inhibits the functions of PCSK9. The patent outlines the use of this compound, along with its pharmaceutically acceptable salts or solvates, as an active component in medicaments aimed at preventing or treating symptoms, diseases, or disorders associated with PCSK9 functions. He has 1 patent to his name.
Career Highlights
Throughout his career, Matteo has worked with esteemed organizations, including The Kitasato Institute and Lipoprotein Research Stockholm AB. His experience in these institutions has allowed him to refine his expertise in lipid research and pharmaceutical development.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Matteo Pedrelli's innovative work in PCSK9 inhibition represents a significant advancement in pharmaceutical science. His contributions are vital for the development of new treatments for cholesterol-related disorders.